8-[2-(3'-benzyloxybiphenyl-4-yl)ethylamino]-2',3',5'-tris-O-(tert-butyldimethylsilyl)adenosine | 880158-41-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 8-[2-(3'-benzyloxybiphenyl-4-yl)ethylamino]-2',3',5'-tris-O-(tert-butyldimethylsilyl)adenosine
• 英文别名: 8-[2-(3'-Benzyloxybiphenyl-4-yl)ethyl-amino]-2',3',5'-tris-o-(tert-butyldimethylsilyl)adenosine；9-[(2R,3R,4R,5R)-3,4-bis[[tert-butyl(dimethyl)silyl]oxy]-5-[[tert-butyl(dimethyl)silyl]oxymethyl]oxolan-2-yl]-8-N-[2-[4-(3-phenylmethoxyphenyl)phenyl]ethyl]purine-6,8-diamine
• CAS: 880158-41-8
• 化学式: C₄₉H₇₄N₆O₅Si₃
• 分子量: 911.42
• InChiKey: CMXANMQXJPLUDR-WTZZGMGRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  12.01
• 重原子数：
  63
• 可旋转键数：
  19
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  128
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  8-[2-(3'-benzyloxybiphenyl-4-yl)ethylamino]-2',3',5'-tris-O-(tert-butyldimethylsilyl)adenosine 在 10% Pd/C 氢气 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Purinenucleoside derivative modified in 8-position and medical use thereof

  摘要：

  本发明提供了一种用于与血浆尿酸水平异常相关疾病的8-修饰嘌呤核苷衍生物。以下式（I）所代表的一种8-修饰嘌呤核苷衍生物、其前药或药用盐、或其水合物或溶剂化合物，对于痛风、高尿酸血症、尿路结石、高尿酸性肾病等的预防或治疗具有用处。在该式中，n为1或2；RA是氢原子或羟基；R1是氢原子、羟基、硫醇基、氨基或氯原子；环J代表可选地取代的2-萘基，或由以下一般式（II）所代表的基团，其中Y代表单键或连接基团；环Z代表可选地取代的芳基或杂环芳基等；而R2至R4、P1和Q代表卤素原子、氰基或类似物。

  公开号：

  US20070179115A1

文献信息

• Purine nucleoside derivative modified in 8-position and medical use thereof
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US07795236B2

  公开（公告）日：2010-09-14

  The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R2 to R4, P1 and Q represents a halogen atom, a cyano group or the like.

  本发明提供了一种8-修饰嘌呤核苷衍生物，该衍生物对于与血浆尿酸水平异常相关的疾病具有用途。式（I）所表示的8-修饰嘌呤核苷衍生物，其前药或其药学上可接受的盐，或其水合物或溶剂化物，对于痛风、高尿酸血症、尿路结石、高尿酸性肾病等的预防或治疗有用。 在式中，n为1或2；RA为氢原子或羟基；R1为氢原子、羟基、硫醇基、氨基或氯原子；环J代表一个可选择取代的2-萘基团，或由下述通式（II）所表示的团基，其中Y表示单键或连接基；环Z代表一个可选择取代的芳基团或杂环芳基团等；而R2至R4、P1和Q代表卤素原子、氰基或类似物。
• PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF
  申请人：Tatani Kazuya

  公开号：US20100249054A9

  公开（公告）日：2010-09-30

  The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; R A is a hydrogen atom or a hydroxyl group; R 1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R 2 to R 4 , P 1 and Q represents a halogen atom, a cyano group or the like.

  本发明提供了一种8-修饰嘌呤核苷衍生物，用于与血浆尿酸水平异常相关的疾病。公式（I）所表示的8-修饰嘌呤核苷衍生物，其前体药物或其药学上可接受的盐，或其水合物或溶剂化物，可用于痛风、高尿酸血症、泌尿系结石、高尿酸性肾病等的预防或治疗。在公式中，n为1或2；RA是氢原子或羟基；R1是氢原子、羟基、硫醇基、氨基或氯原子；环J表示可选取的2-萘基团，或由以下通式（II）所表示的基团，其中Y表示单键或连接基团；环Z表示可选取的芳基团或杂环芳基团等；R2到R4、P1和Q表示卤素原子、氰基或类似物。